Cargando…

Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists

The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Helen, Korbonits, Márta
Formato: Texto
Lenguaje:English
Publicado: BioScientifica 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761811/
https://www.ncbi.nlm.nih.gov/pubmed/19729432
http://dx.doi.org/10.1530/EJE-09-0511
_version_ 1782172856814141440
author Butler, Helen
Korbonits, Márta
author_facet Butler, Helen
Korbonits, Márta
author_sort Butler, Helen
collection PubMed
description The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.
format Text
id pubmed-2761811
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioScientifica
record_format MEDLINE/PubMed
spelling pubmed-27618112009-11-01 Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists Butler, Helen Korbonits, Márta Eur J Endocrinol Review The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists. BioScientifica 2009-11 /pmc/articles/PMC2761811/ /pubmed/19729432 http://dx.doi.org/10.1530/EJE-09-0511 Text en © 2009 European Society of Endocrinology http://www.bioscientifica.com/journals/reuselicenceeje/ This is an Open Access article distributed under the terms of the European Journal of Endocrinology's Re-use Licence (http://www.bioscientifica.com/journals/reuselicenceeje/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Butler, Helen
Korbonits, Márta
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title_full Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title_fullStr Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title_full_unstemmed Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title_short Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
title_sort cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761811/
https://www.ncbi.nlm.nih.gov/pubmed/19729432
http://dx.doi.org/10.1530/EJE-09-0511
work_keys_str_mv AT butlerhelen cannabinoidsforclinicianstheriseandfallofthecannabinoidantagonists
AT korbonitsmarta cannabinoidsforclinicianstheriseandfallofthecannabinoidantagonists